MIM
KPTI icon

MetLife Investment Management’s Karyopharm Therapeutics KPTI Stock Holding History

MetLife Investment Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,037
Closed -$91.4K – 2907
2024
Q1 		$91.4K Buy
+4,037
New +$70.8K ﹤0.01% 2577
2023
Q4 		– Sell
-4,016
Closed -$80.7K – 2848
2023
Q3 		$80.7K Hold
4,016
– – ﹤0.01% 2691
2023
Q2 		$108K Buy
4,016
+1,264
+46% +$54.4K ﹤0.01% 2629
2023
Q1 		$161K Buy
2,752
+792
+40% +$39.1K ﹤0.01% 2350
2022
Q4 		$99.9K Sell
1,960
-801
-29% -$55.5K ﹤0.01% 2593
2022
Q3 		$226K Buy
2,761
+1,213
+78% +$90.6K ﹤0.01% 2215
2022
Q2 		$105K Sell
1,548
-1,237
-44% -$113K ﹤0.01% 2694
2022
Q1 		$308K Buy
2,785
+985
+55% +$123K ﹤0.01% 2077
2021
Q4 		$174K Buy
1,800
+1,163
+183% +$116K ﹤0.01% 2142
2021
Q3 		$55.6K Sell
637
-944
-60% -$98K ﹤0.01% 2523
2021
Q2 		$245K Hold
1,581
– – ﹤0.01% 2027
2021
Q1 		$249K Sell
1,581
-518
-25% -$109K ﹤0.01% 1933
2020
Q4 		$487K Hold
2,099
– – ﹤0.01% 1509
2020
Q3 		$460K Hold
2,099
– – 0.01% 1407
2020
Q2 		$596K Buy
2,099
+383
+22% +$113K 0.01% 1286
2020
Q1 		$495K Sell
1,716
-248
-13% -$68.4K 0.01% 1222
2019
Q4 		$565K Hold
1,964
– – 0.01% 1393
2019
Q3 		$283K Hold
1,964
– – ﹤0.01% 1738
2019
Q2 		$176K Buy
+1,964
New +$158K ﹤0.01% 2104
2019
Q1 		– Sell
-1,536
Closed -$216K – 2583
2018
Q4 		$216K Hold
1,536
– – ﹤0.01% 1865
2018
Q3 		$392K Hold
1,536
– – ﹤0.01% 1690
2018
Q2 		$392K Buy
1,536
+519
+51% +$128K ﹤0.01% 1554
2018
Q1 		$205K Hold
1,017
– – ﹤0.01% 1877
2017
Q4 		$146K Buy
+1,017
New +$163K ﹤0.01% 2080

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MetLife Investment Management's KPTI Position: Q2 2024 in Review

MetLife Investment Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2024, closing a stake of 4,037 shares — an estimated $91.4K sold.

MetLife Investment Management first reported a position in KPTI in Q4 2017 and held it in 24 quarters. The position peaked at $596K in Q2 2020. 114 funds tracked by Wall St. Rank hold KPTI as of Q2 2024.

  • MetLife Investment Management reported no remaining Karyopharm Therapeutics position as of Q2 2024 after selling out during the quarter.
  • MetLife Investment Management sold 4,037 Karyopharm Therapeutics shares in Q2 2024, an estimated $91.4K.
  • MetLife Investment Management first reported a position in Karyopharm Therapeutics in Q4 2017 and held it in 24 quarters.
  • MetLife Investment Management's Karyopharm Therapeutics position peaked at $596K in Q2 2020.
  • 114 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2024.

Based on MetLife Investment Management's 13F filing for Q2 2024, filed 13 Aug 2024.